前沿速览005期| CAR-T治B淋 前沿览新知
01
在单采前近期接受苯达莫司汀治疗会对接受CAR-T 细胞疗法的大 B 细胞淋巴瘤患者的临床结局产生不良影响
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
第一作者：Iacoboni G
J Clin Oncol. 2023 Oct 24:JCO2301097.
全文网址：https://ascopubs.org/doi/pdf/10.1200/JCO.23.01097?role=tab
02
制备前 CD8(+)T 细胞的特征决定了 CAR-T 对弥漫大 B 细胞淋巴瘤患者的疗效
Characteristics of premanufacture CD8(+)T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
第一作者：Wang Y
Signal Transduct Target Ther. 2023 Oct 25;8(1):409.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598004/
03
CAR-T 细胞和限时伊布替尼联合治疗复发/难治性套细胞淋巴瘤：TARMAC二期研究
CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study
第一作者：Minson AG
Blood. 2023 Oct 26:blood.2023021306.
全文网址：https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2023021306
04
Axicabtagene Ciloleucel治疗复发/难治性惰性非霍奇金淋巴瘤的三年随访分析（ZUMA-5）
Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)
第一作者：Neelapu SS
Blood. 2023 Oct 25:blood.2023021243.
全文网址：https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2023021243
05
肿瘤来源的外泌体可通过外泌体CD19抗原诱导初始激活，但通过TGF-β信号介导损害CD19特异性CAR-T细胞的功能
Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling
第一作者：Hao Y
Front Med. 2023 Oct 23.
全文网址：https://link.springer.com/article/10.1007/s11684-023-1010-1
06
Axicabtagene ciloleucel治疗 PMBCL 的结局优于DLBCL：一项GLA/DRST 登记研究
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
第一作者：Schubert ML
Blood Adv. 2023 Oct 24;7(20):6191-6195.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582836/
07
抗 PD-L1 抗体的启动时机会影响 CD19 CAR-T 细胞疗法治疗大 B 细胞淋巴瘤的疗效/毒性
Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma
第一作者：Hirayama AV
Blood Adv. 2023 Oct 30:bloodadvances.2023011287.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011287/498528/Timing-of-Anti-PD-L1-Antibody-Initiation-Affects
08
在英国接受 CD19 CAR-T 治疗的大 B 细胞淋巴瘤患者的结局随着时间推移得到改善
Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time
第一作者：Boyle S
Br J Haematol. 2023 Oct 17.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19157
09
学术性即时抗 CD19 CAR-T 细胞产品 varnimcabtagene autoleucel（ARI-0001 细胞）在治疗复发/难治性 B 细胞非霍奇金淋巴瘤方面显示出疗效和安全性
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma
第一作者：Martínez-Cibrián N
Br J Haematol. 2023 Oct 31.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19170
10
套细胞淋巴瘤导致的死亡限制了序贯疗法，尤其是首次复发后的治疗：来自澳大利亚和英国的一系列治疗模式和结局
Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom
第一作者：Minson A
Br J Haematol. 2023 Oct 30.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19179
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2023.11-01 valid until 2025.11
供稿与审核：临床开发与医学部